Lignocaine kinetics in cardiac patients and aged subjects

Br J Clin Pharmacol. 1977 Aug;4(4):439-48. doi: 10.1111/j.1365-2125.1977.tb00759.x.


1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half-lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter-patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half-lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4-hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed.

MeSH terms

  • Adult
  • Aged
  • Aging*
  • Half-Life
  • Heart Diseases / blood*
  • Humans
  • Infusions, Parenteral
  • Injections, Intravenous
  • Kinetics
  • Lidocaine / administration & dosage
  • Lidocaine / adverse effects
  • Lidocaine / blood*
  • Male
  • Middle Aged
  • Time Factors


  • Lidocaine